NEUP
Neuphoria TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
Composite grade F from latest DB weights. Momentum 15.0 / Value 53.8
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta +0.0.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
15
Value
54
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $7.00
Why
Momentum15 · Δ7d -
Value54 · Δ7d +0.0
SentimentN/A · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
15
40% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
54
60% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.6
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 15.0 / Value 53.8
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$17.83M
Beta
-
Shares Out
5.4M
P/E (TTM) · Derived
-14.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.12
Rev YoY
-100.0%
EPS YoY
-101.4%
Gross Margin
-
Op Margin
-
Net Debt
-$14.14M
Current Ratio
14.31
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology